These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23409720)

  • 1. Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing.
    Ho HK; Németh G; Ng YR; Pang E; Szántai-Kis C; Zsákai L; Breza N; Greff Z; Horváth Z; Pató J; Szabadkai I; Szokol B; Baska F; Őrfî L; Ullrich A; Kéri G; Chua BT
    Curr Med Chem; 2013; 20(10):1203-17. PubMed ID: 23409720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
    Lu X; Chen H; Patterson AV; Smaill JB; Ding K
    J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theoretical studies on FGFR isoform selectivity of FGFR1/FGFR4 inhibitors by molecular dynamics simulations and free energy calculations.
    Fu W; Chen L; Wang Z; Kang Y; Wu C; Xia Q; Liu Z; Zhou J; Liang G; Cai Y
    Phys Chem Chem Phys; 2017 Feb; 19(5):3649-3659. PubMed ID: 28094372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational Simulation Studies on the Binding Selectivity of 1-(1H-Benzimidazol-5-yl)-5-aminopyrazoles in Complexes with FGFR1 and FGFR4.
    Pan YL; Liu YL; Chen JZ
    Molecules; 2018 Mar; 23(4):. PubMed ID: 29584670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
    Li X; Guise CP; Taghipouran R; Yosaatmadja Y; Ashoorzadeh A; Paik WK; Squire CJ; Jiang S; Luo J; Xu Y; Tu ZC; Lu X; Ren X; Patterson AV; Smaill JB; Ding K
    Eur J Med Chem; 2017 Jul; 135():531-543. PubMed ID: 28521156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
    Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
    Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.
    Tan L; Wang J; Tanizaki J; Huang Z; Aref AR; Rusan M; Zhu SJ; Zhang Y; Ercan D; Liao RG; Capelletti M; Zhou W; Hur W; Kim N; Sim T; Gaudet S; Barbie DA; Yeh JR; Yun CH; Hammerman PS; Mohammadi M; Jänne PA; Gray NS
    Proc Natl Acad Sci U S A; 2014 Nov; 111(45):E4869-77. PubMed ID: 25349422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors.
    Pan C; Nie W; Wang J; Du J; Pan Z; Gao J; Lu Y; Che J; Zhu H; Dai H; Chen B; He Q; Dong X
    Eur J Med Chem; 2021 Dec; 225():113794. PubMed ID: 34488024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BLU-554, A selective inhibitor of FGFR4, exhibits anti-tumour activity against gastric cancer in vitro.
    Zhang X; Zhang X; Han R; Wang Z; Yang Q; Huang Y; Yan Y
    Biochem Biophys Res Commun; 2022 Mar; 595():22-27. PubMed ID: 35093636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel FGFR4 inhibitors through a build-up fragment strategy.
    Kim J; Im CG; Oh K; Lee JM; Al-Rubaye F; Min KH
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2343350. PubMed ID: 38655602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probing Dual Covalent Irreversible Inhibition of EGFR/FGFR4 by Electrophilic-Based Natural Compounds to Overcome Resistance and Enhance Combination Therapeutic Potentials and Management of Hepatocellular Carcinoma (HCC).
    Xue H; Chen P; Jiao J; Zhu X
    Protein J; 2024 Aug; 43(4):793-804. PubMed ID: 38981944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma.
    Jin Q; Zhang D; Gao M; Jiang C; Zhang J
    Bioorg Med Chem; 2021 Jan; 29():115862. PubMed ID: 33218898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of N-(4-((6-(3,5- Dimethoxyphenyl)-9H-purine derivatives as irreversible covalent FGFR inhibitors.
    Wang Y; Pan Y; Lv Z; Gou S
    Eur J Med Chem; 2024 May; 271():116415. PubMed ID: 38643670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
    Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L
    EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4.
    Tucker JA; Klein T; Breed J; Breeze AL; Overman R; Phillips C; Norman RA
    Structure; 2014 Dec; 22(12):1764-1774. PubMed ID: 25465127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel 7-formyl-naphthyridyl-ureas derivatives as potential selective FGFR4 inhibitors: Design, synthesis, and biological activity studies.
    Sun C; Fang L; Zhang X; Gao P; Gou S
    Bioorg Med Chem; 2019 May; 27(10):1932-1941. PubMed ID: 30987781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and optimization of selective FGFR4 inhibitors via scaffold hopping.
    Wang Y; Chen Z; Dai M; Sun P; Wang C; Gao Y; Zhao H; Zeng W; Shen L; Mao W; Wang T; Hu G; Li J; Chen S; Long C; Chen X; Liu J; Zhang Y
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2420-2423. PubMed ID: 28433531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).
    Li SQ; Cheuk AT; Shern JF; Song YK; Hurd L; Liao H; Wei JS; Khan J
    PLoS One; 2013; 8(10):e76551. PubMed ID: 24124571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-cancer effects of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives on hepatocellular carcinoma harboring FGFR4 activation.
    Nam Y; Shin I; Kim Y; Ryu S; Kim N; Ju E; Sim T
    Neoplasia; 2022 Jan; 24(1):34-49. PubMed ID: 34864570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer.
    Turkington RC; Longley DB; Allen WL; Stevenson L; McLaughlin K; Dunne PD; Blayney JK; Salto-Tellez M; Van Schaeybroeck S; Johnston PG
    Cell Death Dis; 2014 Feb; 5(2):e1046. PubMed ID: 24503538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.